Tailored Dose-Dense Versus Standard Adjuvant Chemotherapy for High-Risk Early Breast Cancer: End-of-Study Results of the Randomized PANTHER Trial

Author(s): Alexios Matikas, MD, PhD1,2; Volker Möbus, MD, PhD3; Richard Greil, MD, PhD4; Anne Andersson, MD, PhD5; Günther G. Steger, MD6; Michael Untch, MD, PhD7; Tommy Fornander, MD, PhD1; Per Malmström, MD, PhD8,9; Sabine Schmatloch, MD10; Mats Hellström, BSc2; Hemming Johansson, BSc1; Michael Gnant, MD, PhD11; Yvonne Brandberg, PhD1; Sibylle Loibl, MD, PhD12; Theodoros Foukakis, MD, PhD theodoros.foukakis@ki.se1,2; Jonas Bergh, MD, PhD1,2
Source: https://doi.org/10.1200/JCO.24.00178

Dr. Anjan Patel's Thoughts

Well done study showing a 20% decrease in recurrence risk when using dose dense therapy [EC]/D compared to conventional dose [FEC]/D. Sometimes it is worth it to push.

ABSTRACT

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.

Although dose-dense adjuvant chemotherapy administered once every 2 weeks leads to superior outcomes compared with standard regimens once every 3 weeks, the observed improvement is largely limited to studies using the suboptimal paclitaxel schedule once every 3 weeks as control. PANTHER is an international phase III trial which compared sequential epirubicin/cyclophosphamide and docetaxel administered either once every 2 or once every 3 weeks, with tailored dosing at the dose-dense schedule according to hematologic toxicity. In this end-of-study analysis, the median follow-up was 10.3 years. Compared with standard adjuvant chemotherapy, dose-dense treatment improved breast cancer recurrence-free survival (hazard ratio [HR], 0.80 [95% CI, 0.65 to 0.98]; P = .030), event-free survival (HR, 0.78 [95% CI, 0.65 to 0.94]; P = .009), and distant disease-free survival (HR, 0.79 [95% CI, 0.64 to 0.98]; P = .030) while the improvement in overall survival was not statistically significant (HR, 0.82 [95% CI, 0.65 to 1.04]; P = .109). To our knowledge, this is the first trial that confirms the benefit of a dose-dense regimen over a control regimen containing docetaxel once every 3 weeks.

Author Affiliations

1Oncology/Pathology Department, Karolinska Institutet, Stockholm, Sweden; 2Breast Center, Karolinska Comprehensive Cancer Center, Stockholm, Sweden; 3Department of Medicine II, Hematology & Oncology, University of Frankfurt, Frankfurt, Germany; 43rd Medical Department, Paracelsus Medical University and Salzburg Cancer Research Institute, Cancer Cluster Salzburg and AGMT, Salzburg, Austria; 5Department of Radiation Sciences, Oncology Unit, Umeå University, Umeå, Sweden; 6Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria; 7Helios Klinikum Berlin-Buch, Berlin, Germany; 8Division of Oncology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden; 9Department of Haematology, Oncology and Radiation Physics, Skåne University Hospital, Lund, Sweden; 10Elisabeth Hospital, Kassel, Germany; 11Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; 12German Breast Group, Neu-Isenburg, Germany

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Articles

Phase III Randomized, Placebo-Controlled Clinical Trial of Donepezil for Treatment of Cognitive Impairment in Breast Cancer Survivors After Adjuvant Chemotherapy (WF-97116)

It seems donepezil did not show any cognitive benefit when added to standard adjuvant chemotherapy for breast cancer. Unfortunately, adequate treatment for ‘chemo-brain’ remains elusive. There is data that a lipid structure, S1P, may be linked to this process and may be ‘druggable’ with some of the MS agents.

Read More »

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Datopotamab Deruxtecan is a new ADC that will likely be approved in the near future. The payload is the same as used in Enhertu, but the antibody is directed at TROP2. This report is from the TROPION-pan tumor study and shows a promising ORR in HR+/HER2- MBC. There is reasonable data for this compound in 2L met-NSCLC in the TROPION-LUNG01 study with an improvement in PFS compared to docetaxel of 4.4 vs 3.7 months. Dato also is effective in patients with actionable genetic alterations in the 2L setting. There is also an ongoing study on its use in the 1L setting for met-NSCLC in combination with pembrolizumab and chemotherapy.

Read More »